CRISPRa

CRISPR activation, or CRISPRa, refers to a class of gene regulation techniques that use the CRISPR-Cas9 system to upregulate transcription of endogenous genes without cutting DNA. It relies on a catalytically dead Cas9 (dCas9) or a nickase fused to transcriptional activators, guided by a single-guide RNA to promoter or enhancer regions, thereby increasing gene expression.

Multiple architectural approaches exist. The earliest widely used method attaches an activator such as VP64 to dCas9 (dCas9-VP64). More potent versions employ combinations of activators, for example dCas9-p65-HSF1 or the tripartite VPR system (VP64-p65-Rta). The CRISPR activation mediator (SAM) strategy adds sgRNA scaffolds that recruit MS2-coat protein fused to additional activators, enhancing transcription. The SunTag system uses a dCas9 fused to a repeating peptide array that recruits multiple antibody-fused activation domains, amplifying the signal.

Successful CRISPRa depends on the design and positioning of the guide RNA relative to transcription start sites and regulatory elements, as well as the accessibility of chromatin. Since SpCas9 recognizes an NGG protospacer adjacent motif, PAM availability can influence targeting; alternative Cas variants expand PAM compatibility. Potential off-target transcriptional activation and variable efficacy across cell types are important considerations.

CRISPRa is applied in functional genomics screens, studying gene function, and modeling diseases, as well as exploring therapeutic upregulation of silenced genes in research settings. It has been implemented in diverse organisms, including mammalian cells, plants, and yeast, using delivery methods such as plasmids, viral vectors, or ribonucleoprotein approaches depending on the context.

Limitations include dependence on chromatin state, possible off-target effects, and delivery efficiency. Ethical and regulatory considerations are evolving in clinical contexts.